Anzeige
Mehr »
Login
Donnerstag, 23.03.2023 Börsentäglich über 12.000 News von 687 internationalen Medien
Gamechanger-Ad-hoc: Gewaltiger Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QN2V ISIN: FR0011651694 Ticker-Symbol: 35L 
Frankfurt
23.03.23
08:04 Uhr
2,360 Euro
-0,040
-1,67 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHERECYDES PHARMA Chart 1 Jahr
5-Tage-Chart
PHERECYDES PHARMA 5-Tage-Chart

Aktuelle News zur PHERECYDES PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.02.Following the Announcement of Its Proposed Merger With Erytech, Pherecydes Pharma Completes a €1.5 Million Capital Increase Reserved to Its Historical Shareholders701This capital increase, fully subscribed by Auriga IV Bioseeds, Ouest Ventures III and the pool of shareholders represented by Guy Rigaud, historical shareholders of Pherecydes Pharma, is part...
► Artikel lesen
16.02.By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy4
16.02.Pherecydes Pharma: ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies447Conference call and webcast in English on February 16, 2023 at 8:30am EST 02:30pm CET and in French on the same day at 12pm EST 6pm CET Strategic combination would build on complementary expertise...
► Artikel lesen
PHERECYDES PHARMA Aktie jetzt für 0€ handeln
15.02.Erytech Pharma S.A.: ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies300ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies Conference call and webcast in English on February 16, 2023at 8:30am EST / 02:30pm...
► Artikel lesen
25.01.Pherecydes Pharma Announces Its Participation in Several Scientific and Investor Conferences368Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial...
► Artikel lesen
03.01.Pherecydes Pharma Announces its Financial Agenda for 2023369Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced...
► Artikel lesen
15.12.22Pherecydes Pharma: Minutes of the Combined General Meeting of December 15, 2022382Adoption of all resolutions presented in line with the recommendations of the Board of Directors Implementation of the separation of powers: Thibaut du Fayet appointed Chief Executive...
► Artikel lesen
29.11.22Pherecydes Pharma Announces the Positive Recommendation of the DSMB For the Continuation of Its Phase II Clinical Study PhagoDAIR in Osteoarticular Infections Caused by Staphylococcus aureus314Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant...
► Artikel lesen
16.11.22Pherecydes Pharma Will Present Its Phagogram's Latest Progress During an Oral Session at the Phage Futures US 2022 Conference489Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant...
► Artikel lesen
27.10.22Pherecydes Pharma Publishes Its Half-Year 2022 Financial Results and Provides an Update on Its Development Plan456H1 2022 marked by the reaching of several key development milestones with anti-Staphylococcus aureus phages: Start of the PhagoDAIR Phase II clinical study in the treatment of osteoarticular...
► Artikel lesen
27.09.22Pherecydes Pharma Announces Its Participation in a Number of Major Scientific and Investor Conferences409Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces...
► Artikel lesen
22.09.22Pherecydes Pharma Successfully Completes €3.1 Million Capital Increase458Regulatory News: Not for release, either directly or indirectly, in the United States, Canada, Australia or Japan. Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company...
► Artikel lesen
21.09.22Pherecydes Pharma Launches a Capital Increase for c. €3m to Continue Its Clinical Development Program in Phage Therapy728Global Offering aimed at institutional investors, as well as individual investors via the PrimaryBid platform Subscription commitments totaling at least €2.3 million from longstanding shareholders...
► Artikel lesen
15.09.22Pherecydes Pharma Announces the Creation of an International Medical Advisory Board481This group of infectious diseases experts will contribute to the design and implementation of the Company's clinical development strategy in phage therapy Regulatory News: Pherecydes Pharma...
► Artikel lesen
12.09.22Pherecydes Pharma Announces a First Registration of Its Phagogram as an in Vitro Diagnostic Test in Accordance With EC Directives323This vital tool for precision medicine thus meets regulatory requirements and clinicians' expectations Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology...
► Artikel lesen
27.06.22Pherecydes Pharma: Positive Preclinical Results for Inhaled Phage Therapy Presented to the Reanimation 2022 Conference342A preclinical study demonstrates the benefits of inhaled Pherecydes Pharma phages in treating ventilator-associated pneumonia Regulatory News: Pherecydes Pharma (Paris:ALPHE)(FR0011651694...
► Artikel lesen
15.06.22Pherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus315Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced...
► Artikel lesen
08.06.22Pherecydes Pharma Organizes a Scientific Symposium During the 23rd National Days of Infectiology504Phage therapy in 2022: French experience Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant...
► Artikel lesen
30.05.22Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages432This is the first AAC for a treatment in patients who have failed antibiotic therapy, particularly expected in the context of the fight against antibiotic resistance. Regulatory News: Pherecydes...
► Artikel lesen
23.05.22The General Assembly of Pherecydes Pharma Approves the Evolution of Its Governance Towards a Company with a Board of Directors389The new Board of Directors has appointed Didier Hoch as Chairman and CEO, and Thibaut du Fayet as Deputy CEO Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE, éligible PEA-PME) (Paris:ALPHE)...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1